Literature DB >> 22415638

Is rational antipsychotic polytherapy feasible? A selective review.

Rune Andreas Kroken1, Erik Johnsen.   

Abstract

Antipsychotic polytherapy (APT) has evolved as a common treatment strategy at odds with recommendations from schizophrenia treatment guidelines. The literature on combinations with clozapine as a means to enhance efficacy and with aripiprazole to reduce side effects was reviewed. No solid evidence supporting antipsychotic combinations with clozapine for treatment-resistant patients with schizophrenia was identified. The reason for this may be that most combinations with clozapine increase the D(2)-receptor blockade, and this strategy is probably not efficient for patients with treatment-resistant schizophrenia. Some basic and clinical evidence for the addition of aripiprazole to lower prolactin levels was identified. In conclusion, there is very limited support in the evidence for the feasibility of rational APT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22415638     DOI: 10.1007/s11920-012-0266-y

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  62 in total

1.  Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.

Authors:  W Wolfgang Fleischhacker; Martti E Heikkinen; Jean-Pierre Olié; Wally Landsberg; Patricia Dewaele; Robert D McQuade; Jean-Yves Loze; Delphine Hennicken; Wendy Kerselaers
Journal:  Int J Neuropsychopharmacol       Date:  2010-05-12       Impact factor: 5.176

2.  Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period.

Authors:  Monika Edlinger; Armand Hausmann; Georg Kemmler; Martin Kurz; Ilsemarie Kurzthaler; Thomas Walch; Michaela Walpoth; W Wolfgang Fleischhacker
Journal:  Schizophr Res       Date:  2005-09-01       Impact factor: 4.939

3.  The use of first generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval: the Italian experience in a real-world setting.

Authors:  G Di Sciascio; S Calo; G Amodio; S D'Onofrio; R Pollice
Journal:  Int J Immunopathol Pharmacol       Date:  2011 Jan-Mar       Impact factor: 3.219

Review 4.  Emerging drugs for schizophrenia.

Authors:  Falko Biedermann; W Wolfgang Fleischhacker
Journal:  Expert Opin Emerg Drugs       Date:  2011-05-13       Impact factor: 4.191

Review 5.  Mortality in schizophrenia.

Authors:  Pascal Auquier; Christophe Lançon; Frédéric Rouillon; Malcolm Lader; Catriona Holmes
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-12       Impact factor: 2.890

Review 6.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Authors:  Adrian Newman-Tancredi; Mark S Kleven
Journal:  Psychopharmacology (Berl)       Date:  2011-03-11       Impact factor: 4.530

Review 7.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

Review 8.  Imaging dopamine transmission in schizophrenia. A review and meta-analysis.

Authors:  M Laruelle
Journal:  Q J Nucl Med       Date:  1998-09

9.  Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.

Authors:  Moshe Kotler; Rael D Strous; Ilya Reznik; Sima Shwartz; Abraham Weizman; Baruch Spivak
Journal:  Int Clin Psychopharmacol       Date:  2004-01       Impact factor: 1.659

Review 10.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Authors:  S Leucht; D Arbter; R R Engel; W Kissling; J M Davis
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992

View more
  3 in total

1.  Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness.

Authors:  Erik Johnsen; Rune A Kroken
Journal:  Ther Adv Chronic Dis       Date:  2012-11       Impact factor: 5.091

2.  The Prevalence and Factors Associated With Antipsychotic Polypharmacy in a Forensic Psychiatric Sample.

Authors:  Christian Farrell; Johann Brink
Journal:  Front Psychiatry       Date:  2020-04-17       Impact factor: 4.157

3.  The impact of psychopharmacology on contemporary psychiatry.

Authors:  Ross J Baldessarini
Journal:  Can J Psychiatry       Date:  2014-08       Impact factor: 4.356

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.